THE BRAIN HEALTH MEGATREND
HAS BEGUN

cropped-favicon-phyto.png

We believe there exists an attractive investment opportunity yet to be recognized by the financial community at large – just as was seen in the early years of legal cannabis.

We believe we are at the start of a neurowellness and brain health megatrend. The time has come for people to take care of their mind in the same way they take care of their bodies.

By connecting with the right people and providing venture capital to early industry operators, Phyto helped grow the Cannabis industry from $4 billion in sales in 2015 to nearly $25 billion in 2021.

We have applied this same approach to our new psychedelic-focused fund, Phyto Psyche.

Play Video
>280 million people
suffer from depression globally
Psychedelics may provide solutions
to the global mental health and wellbeing crisis.
300%
The burden of depressive symptoms has tripled since 2019.
31% of patients
have treatment-resistant depression.
1 of every 8 ER visits
are linked to mental health and substance abuse disorders
Less then half
of all U.S. adults with mental health illness received treatment in 2020
71% response rate
of Esketamine + antidepressant therapy demonstrated rapid antidepressant effects in treatment-resistant depression
70% response rate
of Ketamine infusions demonstrating rapid antidepressant effects in treatment-resistant depression
6 academic institutions
have opened dedicated psychedelic research centers
>$730 Million
was invested across 51 psychedelics transactions in 2021

Featured Links

Phyto News

Phyto Partners, LLC
2080 NW Boca Raton Blvd
Boca Raton, FL 33431

561-542-6090

Phyto Partners, LLC
2080 NW Boca Raton Blvd
Boca Raton, FL 33431

561-542-6090